Shuttle Pharmaceuticals Issues Common Stock and Warrants After Special Meeting

What Happened Shuttle Pharmaceuticals Holdings, Inc. filed a Form 8‑K (Sept 16, 2026) reporting that, following its Special Meeting of Stockholders on September 9, 2026, the company issued common stock and warrants as approved by shareholders. As of September 14, 2026, the company issued 2,869,595 shares of common stock upon conversion of Series B‑1 preferred stock and 867,887 shares upon conversion of Series B‑2 preferred stock. The company also issued common stock purchase warrants to buy ~927,114 shares (three‑year term, $10.30 per share exercise price, post‑reverse split) and pre‑funded warrants to buy ~16,932,508 shares.

Key Details

• Meeting and filings: Special Meeting held Sept 9, 2026; voting results previously reported on Form 8‑K filed Sept 11, 2026; this Form 8‑K filed Sept 16, 2026.
• Common shares issued: 2,869,595 (B‑1 conversions) + 867,887 (B‑2 conversions) = 3,737,482 shares issued as of Sept 14, 2026.
• Warrants issued: ~927,114 common stock purchase warrants (3‑year term, $10.30 exercise price, post‑reverse split).
• Pre‑funded warrants: ~16,932,508 pre‑funded warrants issued to purchase common stock.
• Issuances reflect the 4.99% beneficial ownership limitation in the preferred stock terms; forms of the warrants were previously filed and are incorporated by reference.

Why It Matters This filing documents equity issuances that increase the number of outstanding common shares and create potential future dilution if warrants or pre‑funded warrants are exercised. Investors should note the number of shares issued now (3.74M) and the large pool of pre‑funded warrants (~16.93M) that could convert into additional common shares. The warrant exercise price ($10.30, post‑reverse split) and three‑year term set the conditions under which dilution could occur; the beneficial ownership cap may limit immediate conversions for some holders.